Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Abnormal chromosomes forecast leukemia relapse

17.06.2004


Patients with acute myeloid leukemia (AML) who enter remission with abnormal chromosomes in bone marrow cells are twice as vulnerable to recurrence of their disease as are AML patients with normal bone marrow cells at remission, according to a new study.



The findings by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute call for routine testing for chromosomal abnormalities in AML patients at diagnosis and again when patients enter remission.

If verified, the findings mean that AML patients showing chromosomal abnormalities early during remission should be considered for more intensive treatment, such as a bone marrow transplant, in an attempt to prevent a return of the disease. Patients with normal-looking chromosomes can receive standard therapy.


The findings are published in the June 15 issue of the Journal of Clinical Oncology.

“For the first time, we have shown in a relatively large group of patients that someone with AML who has abnormal chromosomes early during remission will relapse, even if blood counts and other parameters are favorable,” says first author Guido Marcucci, associate professor of internal medicine and a hematologist/oncologist with OSU’s James Cancer Hospital.

Since 1990, physicians have said that AML patients were in complete remission following treatment if their blood count was normal, and their bone marrow contained fewer than 5 percent of immature cells known as blasts.

By that definition, 60 percent to 70 percent of AML patients achieve complete remission, but only 30 percent to 40 percent of those patients remain in remission long enough to be considered completely cured of their disease.

“Achieving complete remission is an important step for a successful treatment,” Marcucci says, “but it does not predict who will do well in the long run and who will relapse. We need additional diagnostic indicators like the presence of abnormal chromosomes.”

The study of abnormal chromosomes is known as cytogenetics. Chromosomal, or cytogenetic, abnormalities are seen at diagnosis in about 55 percent of all AML patients. The remaining 45 percent have normal-looking chromosomes, or normal cytogenetics.

The presence of cytogenetic abnormalities at diagnosis has long proven to be one of the most important prognostic factors for AML. Furthermore, the sensitive technology and methods needed for cytogenetic testing, which were formerly found mainly in research laboratories, are now widely available for use in clinical tests.

This retrospective study examined the outcomes of 118 AML patients who had received cytogenetic testing at the time of diagnosis and at the first day of complete remission.

Of these, 103 patients had abnormal chromosomes at diagnosis and normal chromosomes at complete remission. These patients were compared to 15 others who had abnormal chromosomes at both diagnosis and at complete remission.

The results showed that patients with abnormal chromosomes at remission had a significantly shorter survival. They were twice as likely to relapse and die.

Based on their findings, the researchers concluded that converting from abnormal chromosomes to normal chromosomes at remission is an import predictor of long-term outcome in AML, and supports the use of cytogenetics testing at remission

“These findings indicate that the old definition of remission isn’t good enough,” Marcucci says. “We need to include cytogenetic complete remission as a criterion for complete remission in AML.”

Funding from the National Cancer Institute supported this research.


Contact: Darrell E. Ward, Medical Center Communications, 614-293-3737, or Ward-15@medctr.osu.edu

Darrell E. Ward | Ohio State University
Further information:
http://researchnews.osu.edu/archive/amlchrom.htm

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Gold shines through properties of nano biosensors

17.08.2017 | Physics and Astronomy

Greenland ice flow likely to speed up: New data assert glaciers move over sediment, which gets more slippery as it gets wetter

17.08.2017 | Earth Sciences

Mars 2020 mission to use smart methods to seek signs of past life

17.08.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>